Trametinib Dimethyl Sulfoxide
Information
- Drug Name
- Trametinib Dimethyl Sulfoxide
- Description
- Entry(CIViC)
- 3
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| cholangiocarcinoma |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 28480077 | Detail |
| cholangiocarcinoma |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 28078132 | Detail |
| cholangiocarcinoma |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 25435907 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Chemotherapy-refractory, metastatic cholangiocarci... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Two cases of patients with BRAF V600E positive cho... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Dabrafenib and trametinib combination showed durab... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04439318 | Active, not recruiting | Phase 2 | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) | February 25, 2016 | December 31, 2025 |
| NCT04527549 | Active, not recruiting | Phase 2 | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | June 1, 2021 | November 30, 2025 |
| NCT02196181 | Active, not recruiting | Phase 2 | Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery | September 19, 2014 | December 31, 2024 |
| NCT02224781 | Active, not recruiting | Phase 3 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | September 8, 2015 | December 31, 2024 |
| NCT04439357 | Active, not recruiting | Phase 2 | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) | February 25, 2016 | December 31, 2025 |
| NCT01902173 | Active, not recruiting | Phase 1/Phase 2 | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | July 19, 2013 | October 6, 2024 |
| NCT02101788 | Active, not recruiting | Phase 2/Phase 3 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | February 27, 2014 | October 11, 2024 |
| NCT04439279 | Active, not recruiting | Phase 2 | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) | August 12, 2015 | March 5, 2025 |
| NCT04439292 | Active, not recruiting | Phase 2 | Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) | August 12, 2015 | April 2, 2025 |
| NCT02281760 | Completed | Phase 2 | Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease | November 1, 2014 | August 29, 2018 |
| NCT04557956 | Recruiting | Phase 1/Phase 2 | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | August 19, 2021 | December 4, 2024 |
| NCT03919071 | Recruiting | Phase 2 | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | February 20, 2020 | September 30, 2027 |
| NCT03794297 | Withdrawn | Phase 2 | Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations | January 4, 2019 | February 18, 2021 |